DBV Technologies S.A. 10-Q Summary: Q2 2026
Business Context and Reporting Period
DBV Technologies S.A. is a late-stage biopharmaceutical company developing epicutaneous immunotherapy (EPIT) for food allergies, primarily focusing on the VIASKIN Peanut patch. This report covers the quarterly period ended June 30, 2026. The Company is currently preparing for a Biologics License Application (BLA) submission to the U.S. FDA, which has been rescheduled to the third quarter of 2026 following regulatory feedback.
Key Financial Metrics
| Metric (in millions) | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Operating Income | $0.7 | $1.6 | $2.2 |
| Total Operating Expenses | $(51.3) | $(100.1) | $(69.9) |
| Net Loss | $(50.4) | $(98.0) | $(69.0) |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.23) | $(0.58) |
| Cash and Cash Equivalents (End of Period) | $174.9 | $174.9 | $103.2 |
| Net Cash Used in Operating Activities | N/A | $(101.7) | $(53.6) |
| Net Cash Provided by Financing Activities | N/A | $89.0 | $117.0 |
Note: The Company generated no product revenue. Operating income consists entirely of Research Tax Credits.
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased 43% year-over-year (YTD) to $100.1 million, driven by a 1,426% increase in Sales and Marketing expenses ($10.4M vs $0.7M) and a 78% increase in General and Administrative expenses ($25.1M vs $14.1M). This reflects a strategic shift from clinical development to commercial launch readiness.
- Personnel Expansion: Average employee count rose to 170 in H1 2026 from 109 in H1 2025, with significant hiring in the U.S. to support regulatory and commercial functions.
- Financing Activity: The Company received $94.7 million in January 2026 from the full exercise of warrants associated with the March 2025 PIPE financing. No sales were made under the at-the-market (ATM) sales agreement during this period as the Form S-3 registration expired in April 2026.
- Currency Impact: A depreciation of the Euro against the U.S. Dollar resulted in a $5.3 million unfavorable foreign currency translation adjustment in other comprehensive loss.
Guidance, Outlook, and Risks
- BLA Submission: Management anticipates submitting the BLA for VIASKIN Peanut (ages 4-7) in Q3 2026. A submission for toddlers (ages 1-3) is planned for H2 2026, contingent on the completion of the COMFORT Toddlers safety study.
- Liquidity Runway: With $174.9 million in cash as of June 30, 2026, management estimates sufficient funding to support operations into the third quarter of 2027, assuming current cost-containment measures and no new major programs.
- Manufacturing Risks: The Company relies on Fareva Amboise as its sole contract manufacturer for VIASKIN Peanut patches. The FDA has issued warning letters to Fareva regarding cGMP deficiencies. Failure to remediate these issues could materially delay clinical trials or commercialization.
- Commercial Partnerships: Letters of intent were signed with Fareva Amboise for commercial-scale manufacturing (estimated $7.5M investment) and Integrated Commercialization Solutions (ICS) for U.S. distribution support. Definitive agreements are under negotiation.
Investor Verification Checklist
- BLA Timeline: Verify the specific date of the BLA submission in Q3 2026 and confirm FDA acceptance for review.
- Manufacturing Remediation: Monitor the status of Fareva Amboise's response to FDA warning letters and the timeline for cGMP compliance.
- Capital Needs: Assess the expiration of the Form S-3 registration and the Company's ability to raise additional capital if the cash runway shortens due to accelerated commercialization costs.
- Commercial Agreements: Confirm the execution of definitive agreements with Fareva Amboise and ICS, including specific financial terms and obligations.
- Regulatory Milestones: Track the initiation and results of the Phase 2 THRIVE study in infants (6-12 months) and the COMFORT Toddlers study.